Medical and management approaches to the examination of hereditary cancer syndrome patients and their relatives
- Authors: Byakhova M.M.1, Parts S.A.1, Semenova A.B.1, Kuzmina E.S.1, Didenko V.V.1, Galkin V.N.1, Gadzhieva S.M.2
-
Affiliations:
- Moscow City Oncological Hospital No.1, Moscow Healthcare Department
- Moscow Healthcare Department
- Issue: Vol 67, No 6 (2023)
- Pages: 487-493
- Section: HEALTH CARE ORGANIZATION
- Submitted: 25.10.2024
- URL: https://hum-ecol.ru/0044-197X/article/view/637838
- DOI: https://doi.org/10.47470/0044-197X-2023-67-6-487-493
- EDN: https://elibrary.ru/vdlewl
- ID: 637838
Cite item
Full Text
Abstract
Introduction. Genetic testing has become the part of the practice of providing specialized cancer care. This allows not only detecting the further tactics for patient management, but also identifying a risk group for the occurrence of malignant neoplasms (MNP). However, there are still no algorithms for dispensary monitoring of healthy carriers of mutations, which determined the relevance of our study.
The purpose of the study was to propose an organizational model for the work of the office of hereditary tumor pathology (HTP) based on the analysis of our own experience in identifying patients with hereditary oncological syndromes and their relatives as potent carriers of mutations associated with an increased risk of occurring MNP.
Materials and methods. Genetic testing was carried out in two thousand two hundred seventy six patients (residents of Moscow) with breast, gastrointestinal tract, and ovarian cancer.
Results. 714 patients out of 2276 MNP patients had mutations associated with an increased risk of developing cancer. Further, 277 relatives of these patients were invited, and mutations were detected in 143 (51.7%). Based on these data, an management model of the HTP office was proposed as part of the Outpatient Oncology Center (OOC), and the need for specialists to work in the HTP office per 100 thousand people was determined — 0.06 oncologist’s rate, 0.03 doctor’s rate-genetics and 0.03 psychologist rates.
Limitations. This study did not include patients who did not meet the selection criteria, as well as persons under 18 years of age or who isn’t resident of Moscow.
Conclusion. The introduction of genetic testing of patients’ relatives into practice will allow forming risk groups for subsequent dispensary observation, early detection of tumor and precancerous pathology.
Compliance with ethical standards. The study program was approved by the Moscow City Independent Ethical Committee (protocol No. 69 dated 10/13/2020).
Contribution of the authors:
Byakhova M.M. — research concept and design, writing the text, compilation of the list of literature;
Parts S.A. — research concept and design, writing the text, statistical data processing, editing, compilation of the list of literature;
Semenova A.B. — collection and processing of material;
Kuzmina E.S. — collection and processing of material, compilation of the list of literature, editing;
Didenko V.V. — collection and processing of material;
Galkin V.N. — collection and processing of material, editing;
Gadzhieva S.M. — statistical data processing, editing.
All authors are responsible for the integrity of all parts of the manuscript and approval of the manuscript final version.
Acknowledgments. The study was conducted at the expense of a grant from the Department of Health of the City of Moscow (agreement on the provision of a grant in the form of a subsidy from the budget of the city of Moscow GKOB No. 1 1022/2 dated 12/24/2020).
Conflict of interest. The authors declare no conflict of interest.
Received: August 7, 2023
Accepted: October 11, 2023
Published: December 23, 2023
About the authors
Maria M. Byakhova
Moscow City Oncological Hospital No.1, Moscow Healthcare Department
Author for correspondence.
Email: biakhovamm@mail.ru
ORCID iD: 0000-0002-5296-0068
MD, PhD, DSci., Head of the Genetics Laboratory of Center for Pathological Anatomical Diagnostics and Molecular Genetics of the Moscow State Budgetary Healthcare Institution Moscow City Oncological Hospital No. 1, Moscow Healthcare Department, Moscow, 117152, Russian Federation.
e-mail: biakhovamm@mail.ru
Russian Federation
Sergey A. Parts
Moscow City Oncological Hospital No.1, Moscow Healthcare Department
Email: noemail@neicon.ru
ORCID iD: 0009-0003-9954-4584
Russian Federation
Anna B. Semenova
Moscow City Oncological Hospital No.1, Moscow Healthcare Department
Email: noemail@neicon.ru
ORCID iD: 0000-0002-8433-0837
Russian Federation
Evgenia S. Kuzmina
Moscow City Oncological Hospital No.1, Moscow Healthcare Department
Email: noemail@neicon.ru
ORCID iD: 0009-0007-2856-5176
Russian Federation
Vera V. Didenko
Moscow City Oncological Hospital No.1, Moscow Healthcare Department
Email: noemail@neicon.ru
ORCID iD: 0000-0001-9068-1273
Russian Federation
Vsevolod N. Galkin
Moscow City Oncological Hospital No.1, Moscow Healthcare Department
Email: noemail@neicon.ru
ORCID iD: 0000-0002-6619-6179
Russian Federation
Saida M. Gadzhieva
Moscow Healthcare Department
Email: noemail@neicon.ru
ORCID iD: 0009-0008-3455-493X
Russian Federation
References
- Baranova E.E., Bodunova N.A., Vorontsova M.V., Zakharova G.S., Makarova M.V., Rumyantsev P.O. Hereditary cancer syndromes: a modern paradigm. Problemy endokrinologii. 2020; 66(4): 24–34. https://doi.org/10.14341/probl12366 https://elibrary.ru/sxayzn (in Russian)
- Wilson J.M.G., Jungner G. Principles and Practice of Screening for Disease. Geneva; 1968.
- Sultanbaev A.V., Nasretdinov A.F., Galeev M.G., Men’shikov K.V., Musin Sh.I., Sultanbaeva N.I., et al. Breast cancer screening in germline mutation carriers. A literature review. Opukholi zhenskoy reproduktivnoy sistemy. 2023; 19(2): 16–24. https://doi.org/10.17650/1994-4098-2023-19-2-16-24 (in Russian)
- Semenova A.B., Byakhova M.M., Galkin V.N., Parts S.A., Makarova M.V., Nemtsova M.V., et al. Capabilities of molecular genetic methods for effective hereditary cancers detection in individuals with high cancer risk factors. Zdorov’e megapolisa. 2023; 4(2): 30–40. https://clck.ru/37BCRC https://elibrary.ru/kvcmae (in Russian)
- Kaprin A.D., Starinskiy V.V., Shakhzadova G.V. Malignant Neoplasms in Russia in 2021 (Morbidity and Mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost’ i smertnost’)]. Moscow; 2022. (in Russian)
- Merabishvili V.M. Survival of Cancer Patients [Vyzhivaemost’ onkologicheskikh bol’nykh]. St. Petersburg; 2006. (in Russian)
- IARC. Cancer tomorrow. Estimated number of new cases from 2020 to 2040, Both sexes, age [0–85+]. Available at: https://gco.iarc.fr/tomorrow/en/dataviz/isotype
- Collins J.M., Isaacs C. Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer. Breast J. 2020; 26(8): 152–7. https://doi.org/10.1111/tbj.13970
- Lei H., Zhang M., Zhang L., Hemminki K., Wang X.J., Chen T. Overview on population screening for carriers with germline BRCA mutation in China. Front. Oncol. 2022; 12: 1002360. https://doi.org/10.3389/fonc.2022.1002360
- Lubinski J. Breast cancer genetics: 20 years later. Clin. Genet. 2014; 85(1): 5–6. https://doi.org/10.1111/cge.12293
- Lieberman S., Lahad A., Tomer A., Koka S., BenUziyahu M., Raz A., et al. Familial communication and cascade testing among relatives of BRCA population screening participants. Genet. Med. 2018; 20(11): 1446–54. https://doi.org/10.1038/gim.2018.26
- Lee J., Ham J.Y., Park H.Y., Jung J.H., Kim W.W., Kang B., et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci. Rep. 2022; 12(1): 1842. https://doi.org/10.1038/s41598-022-05931-3
- Finlay E., Stopfer J.E., Burlingame E., Evans K.G., Nathanson K.L., Weber B.L., et al. Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet. Test. 2008; 12(1): 81–91. https://doi.org/10.1089/gte.2007.0037
- MacDonald D.J., Sarna L., van Servellen G., Bastani R., Giger J.N., Weitzel J.N. Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genet. Med. 2007; 9(5): 275–82. https://doi.org/10.1097/GIM.0b013e31804ec075
- Cheng X., Gu Z., Sun X., Zhuang Z. Study on the differences of opinions and choices of high-risk breast cancer populations in China before and after genetic testing. Transl. Cancer Res. 2019; 8(8): 2893–905. https://doi.org/10.21037/tcr.2019.11.43
Supplementary files
